Eevia Health lands sales agreement for berry extracts with a minimum contract value of c. SEK 100 million

Eevia Health Plc, ("Eevia" or "The Company"), a leading health ingredient manufacturer from Finland, today announces that it has entered a multi-year sales agreement for the US market with a key international customer.

The agreement is for the supply of a standardized berry extract. The first three years of the sales agreement provides for a minimum contracted total sales of c. SEK 100 million. Eevia considers that there is a potential for extensions after three years. The minimum contract value may vary depending on raw material price fluctuations.

The end customer is an internationally recognized brand leader in the marketplace with a global footprint. The group has sales of USD 1,2 billion in 2019 and offers over 500 premium dietary supplements, including single herbs, vitamins, minerals, and specialty formulas sold under the Company's well recognized brands, in over 60 countries.

Barrington Nutritionals Inc, headquartered in Harrison, New York, U.S., is a party to the Agreement as Eevia's distributor. Stuart Gelbard, the Founder and President of Barrington Nutritionals adds: "We are excited to enter into this agreement with our client and Eevia to formalize our already excellent cooperation. Eevia has proven to be a reliable provider of high-quality organic ingredients with a unique sustainability story. The Barrington team looks forward to working with Eevia in the years to come."

CEO Stein Ulve comments: "This sales agreement secures an important part of our sales revenues for the next few years. It confirms our ability to serve larger world class clients. Furthermore, it enables us to get a return on investments we have made in the last 18 months. It is a confirmation of the competitiveness of our green-chemistry manufacturing platform. We can compete with efficient extraction and purification technologies for polyphenols from Finland."

Eevia is headquartered in Seinäjoki, Finland. As of the end of first quarter 2021, the Company had over 30 full-time employees, up from 8 employees 12 months ago. The total revenue for the full year ended December 31st, 2020, was EUR 2.86m. Growth has accelerated in 2021 and extract sales reached EUR 1.9m in the period 1st January - 31st March, corresponding to 560 percent sales growth compared to the same period prior year. Eevia Health Plc converted to a public company in April and is preparing to list its shares at Spotlight Stock Market in Sweden on June 29th. See also: https://investor.eeviahealth.com/ipo/

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc
Email: [email protected]
Telephone: +358 400 22 5967

Kim Nurmi-Aro, CFO, Eevia Health Plc
[email protected]
+358 504 44 0717

This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on June 11, 2021.

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, is a small, but fast-growing Finnish manufacturer of 100% organically certified plant extracts. The Company addresses significant health problems with bioactive compounds extracted from plant material from the pristine Finnish forests near the Arctic Circle. The extracts, which have scientifically documented health benefits, are sold B2B as ingredients to dietary supplements and food brands globally. The focus is on ingredients that protect human health prophylactically, reducing the risk of deteriorating health. The products are targeted against immune health, low-grade inflammation, eye and brain health problems and metabolic disorders. In its portfolio, Eevia Health has immune-modulating products that have effects on Th1-type cytokines, such as IFN- and TNF-α cell signaling molecules, which are very important in the immune response to pathogens (virus, bacteria).

Most of its raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion. The safe and effective ingredients of high quality, such as high concentrate bilberry anthocyanin extracts (36%) and pine bark extracts (70% oligomeric proanthocyanidins), are certified organic. Eevia Health operates a modern green-chemistry production facility in Finland, located close to the raw materials. The short value-chain enables an environmentally friendly carbon footprint, competitive pricing, and transparency.

The increasing health awareness among consumers, combined with the increased focus on sustainable business models, constitute a strong and significant macro-trend, from which Eevia stands well equipped to capitalize.

To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

Information About Barrington Nutritionals

For the last 30 years, Barrington Nutritionals has made it their mission to provide the nutraceutical, pharmaceutical and functional food industries with the highest quality ingredients, backed by science. With a diverse portfolio of over 100 ingredients, Barrington continues to build relationships with the finest ingredient producers and leading innovators in the health and wellness space. These relationships create opportunities for innovations and exceptional problem-solving capabilities to meet its customers' needs.

To learn more, please visit barringtonnutritionals.com


Positive results from human clinical study concluded on Feno-Chaga® Organic

Eevia Health Plc (" Eevia" or" The Company") has concluded a human clinical study of the effects of Eevia's branded ingredient Feno-Chaga® Organic on Upper-Respiratory Tract Infections (URTIs) and Psychological Mood State with positive and promising results.


Eevia Health Plc Interim Report Quarter 3 - 2021

The Board and CEO of Eevia Health Plc now present the Interim Report for the third quarter of 2021, covering the period 1 July through 30 September 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com


Notice to the Extraordinary General Meeting of Eevia Health Abp

Notice is given to the shareholders of Eevia Health Abp (Plc) to the Extraordinary General Meeting to be held on 9th of December, 2021 at 1.00 pm at the main office of Eevia Health Plc in Koulukatu 14, Seinäjoki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will commence at 12.30 pm.


Correction: Eevia Health's Board of Directors has resolved, subject to approval at an Extraordinary General Meeting, on a directed share issue of SEK 20 million

This is a correction to press release published 10 November, 2021 where the press release lacked a reference to the EU's Market Abuse Regulation (MAR).

The Board of Directors of Eevia Health Plc (publ) ("Eevia" or the "Company") has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the "EGM"), on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The proceeds will primarily be used for investments in increased capacity to better be able to meet current and future demand.


Eevia Health's Board of Directors has resolved, subject to approval at an Extraordinary General Meeting, on a directed share issue of SEK 20 million

The Board of Directors of Eevia Health Plc (publ) ("Eevia" or the "Company") has resolved, subject to the approval by shareholders at an Extraordinary General Meeting (the "EGM"), on a directed new issue of 2,061,856 shares at a subscription price of SEK 9.70 per share (the "Directed Share Issue"), which is expected to raise proceeds to the Company of SEK 20 million before issue costs. The proceeds will primarily be used for investments in increased capacity to better be able to meet current and future demand.


Eevia Health Plc received new sales orders for organic pine bark extract

Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from a leading organic supplement brand for supply of the Fenoprolic® 70 Organic (organic pine bark extract). The sales value of this start order is c.65,000 EUR, but the customer has a strong record on new product launches, and it is therefore expected to create repeat sales of this product going forward.  


Eevia Health Plc - Interim Report Quarter 2 - 2021

The Board and CEO of Eevia Health Plc hereby present the Interim Report for the second quarter 2021, covering the period April 1st through June 30th, 2021. The complete report with tables is attached to this release as a pdf-file. It is also available on the company website at www.eeviahealth.com 


Eevia Health Plc completed first phase of a planned capacity increase and plant improvement

Eevia Health Plc, ("Eevia" or "The Company"), has installed new capacities and automation equipment for processing and evaporation of natural plant extract liquids. As of August 1st, the newly installed machines and technologies are working satisfactorily, with improved yield, productivity, and cost efficiency. These investments support the company's strong growth and strategic positioning, as communicated in the May 2021 information memorandum.


Eevia Health receives new sales orders for organic bilberry extract with a contract value of approx. SEK 3 million

Eevia Health Plc, ("Eevia" or "The Company"), announces that it has received sales orders from Ingredient Plus of Australia for supply of bilberry extract with minimum 36% anthocyanins. The sales value of these orders is c. SEK 3 million, which to be prepaid and delivered in Q3-21.


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted